NCT06447779View on ClinicalTrials.gov

Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

25,000

Participants

Timeline

Start Date

July 13, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Recombinant Zoster Vaccine (CHO Cell)

"0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105.~Intramuscular injection"

BIOLOGICAL

NaCl solution Placebo

0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection

Trial Locations (4)

430070

Hubei Provincial Center for Disease Control and Prevention, Wuhan

450016

Henan Center for Diseases Control and Prevention, Zhengzhou

650022

Yunnan Center For Disease Control and Prevention, Kunming

050021

Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang

Sponsors
All Listed Sponsors
lead

MAXVAX Biotechnology Limited Liability Company

INDUSTRY

NCT06447779 - Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older | Biotech Hunter | Biotech Hunter